#Liver-Fat

2 stories

Clinical Trials June 8, 2026 · View digest

Boehringer Survodutide SYNCHRONIZE-1 Pre-Specified Body Composition: 34% Visceral Fat and 63% Liver Fat Reduction, Lean Mass Preserved

Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.

Clinical Trials May 5, 2026 · View digest

Retatrutide Cut Liver Fat 86% at 48 Weeks in a Phase 2 Substudy; Lilly's Phase 3 SYNERGY-Outcomes Liver Trial Is Enrolling

In a 98-person substudy of the Phase 2 retatrutide obesity trial, published in Nature Medicine in 2024, liver fat fell 86.0% from baseline at 48 weeks on 12 mg versus 4.6% on placebo, and 93% of people on that dose with week-48 scans reached normal liver fat (below 5%); fewer than half of participants had week-48 MRIs. Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028), which began in October 2025, is enrolling about 4,500 adults with MASLD at higher risk of serious liver outcomes to test retatrutide and tirzepatide against placebo, with time to the first major adverse liver outcome as its main endpoint.